β - Lactam Antibiotics in Clinical Medicine
| Autor: | Robert B. Kammer |
|---|---|
| Rok vydání: | 1982 |
| Předmět: |
biology
business.industry medicine.drug_class Cephalosporin Antibiotics medicine.disease Staphylococcal infections medicine.disease_cause Antimicrobial biology.organism_classification Microbiology Penicillin Staphylococcus aureus Staphylococcus epidermidis Immunology Medicine Syphilis business medicine.drug |
| DOI: | 10.1016/b978-0-12-506303-6.50010-8 |
| Popis: | Publisher Summary This chapter discusses the changing clinical role of various β-lactam antibiotics against a historical pattern. These compounds are evaluated in vitro against a variety of clinical pathogens to determine which compounds possess the potency required for an infection model evaluation. Penicillin G remains a very useful antibiotic for most infections caused by grampositive cocci, excluding staphylococci. Penicillin is no longer clinically useful for staphylococcal infections in developed areas of the world as both staphylococcus aureus and staphylococcus epidermidis have become almost totally resistant. The major indications for penicillin G in the 1980s were streptococcal pneumonia, streptococcal and meningococcal meningitis, group A streptococcal infections, streptococcal endocarditis, syphilis, and most gonorrhea. The early cephalosporins continue to be excellent antistaphylococcal agents in penicillin-allergic patients. However, the increasing incidence of methicillin resistance may limit their clinical application. Although β-lactam research has provided new and better treatment alternatives, the presence of staphylococci resistant to all β-lactams tested, the frequent isolation of multiply-resistant Serratia sp. and Klebsiella sp., and the failure to find the ideal drug for Pseudomonas aeruginosa infections all demand a continuing and intensive research program in this area of antimicrobial therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|